Last reviewed · How we verify
Insulin-Levemir
Insulin-Levemir is a Long-acting basal insulin analog Small molecule drug developed by Novo Nordisk A/S. It is currently FDA-approved for Type 1 diabetes mellitus, Type 2 diabetes mellitus. Also known as: Levemir.
Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.
Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin-Levemir |
|---|---|
| Also known as | Levemir |
| Sponsor | Novo Nordisk A/S |
| Drug class | Long-acting basal insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin detemir is a recombinant human insulin analog modified with a 14-carbon fatty acid chain that allows it to bind reversibly to albumin in the bloodstream, resulting in a prolonged and peakless duration of action (up to 24 hours). This extended half-life enables once or twice-daily dosing for basal insulin replacement in diabetes management. Like all insulins, it works by activating insulin receptors on muscle, fat, and liver cells to promote glucose uptake and storage while inhibiting gluconeogenesis.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Insulin Detemir in Obesity Management (NA)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes (PHASE1)
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER) (PHASE4)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin-Levemir CI brief — competitive landscape report
- Insulin-Levemir updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI
Frequently asked questions about Insulin-Levemir
What is Insulin-Levemir?
How does Insulin-Levemir work?
What is Insulin-Levemir used for?
Who makes Insulin-Levemir?
Is Insulin-Levemir also known as anything else?
What drug class is Insulin-Levemir in?
What development phase is Insulin-Levemir in?
What are the side effects of Insulin-Levemir?
What does Insulin-Levemir target?
Related
- Drug class: All Long-acting basal insulin analog drugs
- Target: All drugs targeting Insulin receptor
- Manufacturer: Novo Nordisk A/S — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 1 diabetes mellitus
- Indication: Drugs for Type 2 diabetes mellitus
- Also known as: Levemir
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing